59760-01-9

Basic information

• Product Name: (S)-(-)-2-OXO-1,5-IMIDAZOLIDINEDICARBOXYLIC ACID 1-BENZYL ESTER
• Synonyms: (S)-(-)-2-OXO-1,5-IMIDAZOLIDINEDICARBOXYLIC ACID 1-BENZYL ESTER;(S)-(-)-2-oxo-1,5-imidazolidine-dicarboxylic acid;(S)-2-OXO-IMIDAZOLIDINE-1,5-DICARBOXYLIC ACID 1-BENZYL ESTER;2-oxo-1,5-imidazolidinedicarboxylic acid, 1-benzyl ester;(4S)-3-[(Benzyloxy)carbonyl]-2-oxoimidazolidine-4-carboxylic acid;(S)-3-CBZ-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID;(S)-()-1-Cbz-2-Oxo-5-iMidazolidinecarboxylic acid;(S)-(-)-1-Z-2-Oxo-5-iMidazolidinecarboxylic acid
• CAS NO: 59760-01-9
• Molecular Formula: C₁₂H₁₂N₂O₅
• Molecular Weight: 264.23
• Product Categories: Chiral Building Blocks;Heterocyclic Building Blocks;Imidazolines/Imidazolidines
• Mol File: 59760-01-9.mol

Chemical Properties

• Melting Point: 189 °C (dec.)(lit.)
• Appearance: /
• Density: 1.444g/cm3
• Refractive Index: 1.598
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.22±0.20(Predicted)
• CAS DataBase Reference: (S)-(-)-2-OXO-1,5-IMIDAZOLIDINEDICARBOXYLIC ACID 1-BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(-)-2-OXO-1,5-IMIDAZOLIDINEDICARBOXYLIC ACID 1-BENZYL ESTER(59760-01-9)
• EPA Substance Registry System: (S)-(-)-2-OXO-1,5-IMIDAZOLIDINEDICARBOXYLIC ACID 1-BENZYL ESTER(59760-01-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 59760-01-9(Hazardous Substances Data)

Usage

Uses

Z-protected imidazolidinone for sequential N-alkylation.

InChI:InChI=1/C12H12N2O5/c15-10(16)9-6-13-11(17)14(9)12(18)19-7-8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,17)(H,15,16)/t9-/m0/s1

Upstream product

• 4474-86-6 (R)-4-amino-2-(((benzyloxy)carbonyl)amino)-4-oxobutanoic acid 
• 2304-96-3 N-benzyloxycarbonyl-L-asparagine 

Downstream Products

• 89384-29-2 benzyl (4S)-3-(benzyloxycarbonyl)-2-oxoimidazolidine-4-carboxylate 
• 77999-24-7 (S)‐2‐oxoimidazolidine‐1,5‐dicarboxylate-5‐tert‐butyl ester-1‐benzyl ester 
• 168399-08-4 methyl 3-benzyloxycarbonyl-2-oxo-imidazolidine-4(S)-carboxylate 
• 872619-06-2 (1'S,2'R,5'S)-menthyl 3-benzyloxycarbonyl-2-oxoimidazolidine-4(S)-carboxylate 
• 117560-19-7 tert-butyl (4S)-1-(benzyloxycarbonyl)-2-oxoimidazolidine-4-carboxylate 
• 83056-78-4 tert-butyl (4S)-3-(benzyloxycarbonyl)-1-methyl-2-oxoimidazolidine-4-carboxylate 
• 89371-89-1 benzyl (4S)-3-(benzyloxycarbonyl)-1-methyl-2-oxoimidazolidine-4-carboxylate 
• 83057-00-5 (S)-3-benzyl-2-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-t-butyl ester 
• 89371-94-8 benzyl (4S)-1-n-butyl-3-benzyloxycarbonyl-2-oxo-imidazolidine-4-carboxylate 
• 89371-88-0 benzyl (4S)-1-benzyl-3-benzyloxycarbonyl-2-oxo-imidazolidine-4-carboxylate 
• 117560-18-6 (S)-3-[(S)-2-((S)-1-Benzyloxycarbonyl-3-phenyl-propylamino)-propionyl]-2-oxo-imidazolidine-1,4-dicarboxylic acid 1-benzyl ester 4-tert-butyl ester; compound with (Z)-but-2-enedioic acid 
• 117560-17-5 (S)-3-[(S)-2-((S)-1-Benzyloxycarbonyl-3-phenyl-propylamino)-propionyl]-2-oxo-imidazolidine-1,4-dicarboxylic acid 1-benzyl ester 4-tert-butyl ester 
• 845543-46-6 (S)-1-benzyl 4-tert-butyl 3-methyl-2-oxoimidazolidine-1,4-dicarboxylate 
• 98649-15-1 1‐benzyl 4‐methyl 3‐methyl‐2‐oxoimidazolidine‐1,4‐dicarboxylate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER

The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))

Pyridine ketone compound and its composition and use thereof (by machine translation)

The invention relates to the field of blood coagulation. In particular, the invention relates to a pyridone compound, or a stereoisomer thereof, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug and pharmaceutical composition containing the compound. The invention also relates to such compounds and pharmaceutical composition preparation method, and they in preparing for the prevention, treatment or alleviation of patient Xa factor relative thromboembolic disease in use. (by machine translation)

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor

A backup molecule to compound 2 was sought by targeting the most likely metabolically vulnerable site in this molecule. Compound 18 was subsequently identified as a potent P2X7 antagonist with very low in vivo clearance and high oral bioavailability in all species examined. Some evidence to support the role of P2X7 in the etiology of pain is also presented.

Synthesis of dirhodium(II) tetrakis[methyl 1-(3-phenylpropanoyl)-2- oxaimidazolidine-4(S)-carboxylate], Rh2(4S-MPPIM)4

The large-scale synthesis with greatly improved yields of methyl 1-(3-phenylpropanoyl)-2-oxaimidazolidine-4(S)-carboxylate and the chiral dirhodium(II) carboxamidate derived from it, Rh2(4S-MPPIM) 4, is described. The key step in the

First attempts at differential diastereoselection in catalytic reactions of N-chirally substituted dirhodium(II) tetrakis[methyl 2-oxoimidazolidine-4(S)-carboxylates] with diazoacetates

Chiral attachments on 2-oxoimidazolidine-4(S)-carboxylate ligands for dirhodium(II) can provide differential diastereoselection in catalytic reactions of diazo compounds. The synthesis of these heterocyclic ligands from the readily available amino acid as